Deep Dive: How Billions are Allocated to Cure Aging
Chamath Palihapitiya
· Chamath Palihapitiya
· June 26, 2026 at 15:03
· ⏱ 4 min read
| Read on Substack ↗
Summary
The article argues that cellular reprogramming, particularly partial reprogramming using Yamanaka factors, is the leading bet among tech billionaires to reverse aging, with potential to restore tissue function without triggering tumor formation. It presents this approach within a four-strategy framework, but offers no specific investment recommendations or market-adjacent data, making it purely educational for markets.
•Yamanaka factors (four proteins) can reset adult cells to an embryonic-like state, earning Shinya Yamanaka the 2012 Nobel Prize.
•Partial reprogramming (short exposure to Yamanaka factors) improves cellular function without erasing specialization, lowering tumor risk.
•Animal studies show partial reprogramming speeds muscle regeneration, reduces scar formation, and reverses vision loss previously thought permanent.
•The article classifies all longevity biotech bets using two axes: buy-time vs stop/reverse aging, and understanding-required vs agnostic.
•Social Capital partnered with researchers to produce a two-part deep dive; part one covered aging biology and bottlenecks, part two covers the four approaches.